A recent study indicates that the use of statins may reduce the risk of developing open-angle glaucoma, a leading cause of blindness worldwide. Researchers analyzed data from a database encompassing 165 million individuals to assess whether statin use was linked to a decreased incidence of the condition.

Over a five-year period, 4,771 individuals taking statins were diagnosed with glaucoma, representing 2.3 percent of that group. In comparison, 5,491 people who were not on statins developed the disease, equating to 2.6 percent of that population. The findings suggest that statin users had approximately a 15 percent lower risk of developing open-angle glaucoma compared to non-users.

Open-angle glaucoma is characterized by progressive damage to the optic nerve, often associated with increased intraocular pressure, which can lead to irreversible vision loss if untreated. Current treatments primarily focus on lowering eye pressure, but preventive strategies remain limited, which makes these findings particularly noteworthy.

The study, published in the British Journal of Ophthalmology, provides evidence supporting statins’ potential protective effect beyond their well-established role in managing cholesterol and cardiovascular risk. While the mechanism through which statins might confer protection against glaucoma is not fully understood, some researchers propose that their anti-inflammatory and neuroprotective properties could play a role.

Further research is required to confirm these results and to clarify whether statins could be recommended as a preventive measure against glaucoma in clinical practice. Experts caution that patients should not start or stop statin therapy solely based on this evidence without consulting healthcare providers.

This investigation adds to a growing body of work examining the broader benefits of statins, highlighting the need for continued exploration of their impact on eye health and other conditions.